The FDA's Reversal On uniQure's Gene Therapy For Huntington's Is a Disaster For Medical Innovation
The FDA’s new restrictive approach to rare disease therapies undermines confidence in regulatory consistency and impedes medical progress. After AMT-130 reduced disease progression by 75% in a phase I/II study, the agency’s reversal threatens to delay a breakthrough.